|
|
| ERYTHROMYEZ 250™ |
| |
 |
| |
| Pharmaceutical Name |
: |
Erythromycin |
| Proprietary Name |
: |
Erythromyez 250TM |
| Dosage form |
: |
250mg/Tablet |
|
| |
|
| |
Erythromyez 250TM is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. In structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinose and D-desosamine), making it a compound very difficult to produce via synthetic methods. Erythromycin is easily inactivated by gastric acid; therefore, all orally-administered formulations are given as either enteric-coated or more-stable laxatives or esters, such as erythromycin ethylsuccinate. Erythromycin is very rapidly absorbed, and diffuses into most tissues and phagocytes. Due to the high concentration in phagocytes, erythromycin is actively transported to the site of infection, where, during active phagocytosis, large concentrations of erythromycin are released. |
| |
|
| |
|
| |
|
|
|
| |
| |
| |
|
